{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Eylea&page=11", "query": { "intervention": "Eylea", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 269, "total_pages": 27, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Eylea&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Eylea&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T03:06:41.397Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06116890", "title": "Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neovascular Age-Related Macular Degeneration (nAMD)" ], "interventions": [ { "name": "KHK4951", "type": "DRUG" }, { "name": "Aflibercept Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyowa Kirin Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 170, "start_date": "2024-01-31", "completion_date": "2026-07-01", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-20T03:06:41.397Z", "location_count": 38, "location_summary": "Mesa, Arizona • Tucson, Arizona • Arcadia, California + 34 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Encino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06116890" }, { "nct_id": "NCT02949024", "title": "Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "IVT Aflibercept", "type": "DRUG" }, { "name": "SC CLS-TA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clearside Biomedical, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2016-11-10", "completion_date": "2017-10-17", "has_results": true, "last_update_posted_date": "2021-05-13", "last_synced_at": "2026-10-20T03:06:41.397Z", "location_count": 2, "location_summary": "Mountain View, California • The Woodlands, Texas", "locations": [ { "city": "Mountain View", "state": "California" }, { "city": "The Woodlands", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02949024" }, { "nct_id": "NCT07630649", "title": "Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD" ], "interventions": [ { "name": "Ixo-vec", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Adverum Biotechnologies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 15, "start_date": "2026-06-02", "completion_date": "2031-06", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-10-20T03:06:41.397Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Bakersfield, California • Fullerton, California + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07630649" }, { "nct_id": "NCT04611152", "title": "A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "KSI-301", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" }, { "name": "Sham Procedure", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Kodiak Sciences Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 460, "start_date": "2020-09-30", "completion_date": "2023-08-31", "has_results": true, "last_update_posted_date": "2024-08-22", "last_synced_at": "2026-10-20T03:06:41.397Z", "location_count": 48, "location_summary": "La Jolla, California • Redlands, California • Santa Maria, California + 44 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "Santa Maria", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Lakewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04611152" }, { "nct_id": "NCT04567550", "title": "RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Retinopathy (DR)", "Center-Involved Diabetic Macular Edema (CI-DME)" ], "interventions": [ { "name": "ABBV-RGX-314 Dose 1", "type": "GENETIC" }, { "name": "ABBV-RGX-314 Dose 2", "type": "GENETIC" }, { "name": "ABBV-RGX-314 Dose 3", "type": "GENETIC" }, { "name": "Topical Steroid", "type": "DRUG" }, { "name": "ABBV-RGX-314 Dose 4", "type": "GENETIC" }, { "name": "Aflibercept", "type": "BIOLOGICAL" } ], "intervention_types": [ "GENETIC", "DRUG", "BIOLOGICAL" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "25 Years to 89 Years" }, "enrollment_count": 139, "start_date": "2020-11-20", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-20T03:06:41.397Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 21 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Campbell", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04567550" }, { "nct_id": "NCT01495221", "title": "To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy)" ], "interventions": [ { "name": "Alfilbercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vitreous -Retina- Macula Consultants of New York", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 9, "start_date": "2011-12", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2018-09-07", "last_synced_at": "2026-10-20T03:06:41.397Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01495221" }, { "nct_id": "NCT02713204", "title": "Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neovascular Age-Related Macular Degeneration" ], "interventions": [ { "name": "REGN910-3", "type": "DRUG" }, { "name": "Intravitreal Aflibercept Injection (IAI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 365, "start_date": "2016-03-31", "completion_date": "2017-10-03", "has_results": true, "last_update_posted_date": "2019-05-07", "last_synced_at": "2026-10-20T03:06:41.397Z", "location_count": 87, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02713204" }, { "nct_id": "NCT03297684", "title": "Assessment of Biomarker Profile in Diabetic Macular Edema With Intravitreal Aflibercept Injection", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "Aflibercept Injection [Eylea]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advanced Eye Research Associates", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 40, "start_date": "2018-04-11", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2022-02-18", "last_synced_at": "2026-10-20T03:06:41.397Z", "location_count": 1, "location_summary": "South Dartmouth, Massachusetts", "locations": [ { "city": "South Dartmouth", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03297684" }, { "nct_id": "NCT04270747", "title": "A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neovascular (Wet) Age-related Macular Degeneration (AMD)" ], "interventions": [ { "name": "ABP 938", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 576, "start_date": "2020-06-22", "completion_date": "2023-01-30", "has_results": true, "last_update_posted_date": "2025-09-10", "last_synced_at": "2026-10-20T03:06:41.397Z", "location_count": 41, "location_summary": "Phoenix, Arizona • Fullerton, California • La Jolla, California + 36 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Desert", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04270747" }, { "nct_id": "NCT00519285", "title": "Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms", "Neoplasm Metastasis" ], "interventions": [ { "name": "Aflibercept", "type": "DRUG" }, { "name": "Placebo (for aflibercept)", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Prednisone or Prednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1224, "start_date": "2007-08", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2016-07-22", "last_synced_at": "2026-10-20T03:06:41.397Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00519285" } ] }